L. (2009). Laboratory monitoring of heparin therapy: Partial thromboplastin time or anti-Xa assay? LabMedicine, 40, 47-51.Lehman, C. M. (2009). Laboratory monitoring of heparin therapy: Partial thromboplastin time or anti-Xa assay? Laboratory Medicine, 40, 47-51....
精准监测之Anti-Xa 精准监测之Anti-Xa 抗Xa活性测定，可针对临床上广泛用于预防和治疗血栓性疾病的抗凝血药物—普通肝素和低分子肝素的药效进行监测，较传统的实验室监测方法APTT，抗Xa活性测定方法更为特异，检测结果稳定，可以更真实地体现病人体内的抗凝效果。本文参考相关国内外文献及临床指南/共识，对肝素监测的两...
Why your lab should perform anti-Xa testing for anticoagulants To monitor and manage bleeding risks, labs are asked to safeguard anticoagulant therapies such as heparin or direct oral anticoagulants (DOACs) by testing patients for a growing number of agents. ...
Heparin The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Heparin. Hydrogen peroxide Hydrogen peroxide may increase the thrombogenic activities of Antihemophilic factor, human recombinant. Lepirudin The therapeutic efficacy of Antihemophilic fac...
Although the activated partial thromboplastin time (aPTT) has historically been the method of choice for anticoagulation monitoring in patients undergoing mechanical circulatory support with intravenous unfractionated heparin, it is being progressively superseded by the anti-factor Xa (anti-Xa) method. A ...
heparin plasma(n=5) 95-105 101 Precision Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Anti-Growth Hormone Antibody (Anti-GHAb) were tested 20 times on one plate, respectively. Inter-assay Precision (Precision between assays): 3 samples wi...
Anti-factor Xa Microdialysis Microfluidic Real-time monitoring Therapeutic drug monitoring Abbreviations UFH unfractionated heparin LMWH low molecular weight heparin 1. Introduction Vascular thrombosis can occur in both arterial and venous circulation and is the leading cause of cardiovascular morbidity and mor...
The successful reprogramming of impaired wound healing presents ongoing challenges due to the impaired tissue microenvironment caused by severe bacterial infection, excessive oxidative stress, as well as the inappropriate dosage timing during different s
Pathol. Lab. Med. 101:6-9), or heparin-induced thrombocytopenia (Rhodes (1973) Surg. Gynecol. Obstet. 136:409-416). Evidence for organ damage of thrombotic occlusion and hypoxic origin is also available in other disease groups, such as hemorrhagic fevers (Dennis (1969) Br. J. Haematol. ...
6.The anti-cancer agent of claim 5, wherein the protein C inhibitor derivative is a protein capable of binding to either or both of heparin and heparin-like glycosaminoglycan. 7.The anti-cancer agent of claim 1, wherein the agent suppresses cancer infiltration. ...